Clinical stage antimicrobials that address AMR

Product or Service Two phase 3 ready antibacterial assets which prevent infection

Both products address AMR and spare antibiotic use

Technology:
  • Infection prevention
  • Antimicrobial compound/strategy

Microorganisms:
  • Bacteria
  • Viruses

Application:
  • Human

Development stage:
  • Research
  • Development

Organization:
  • Company

Partnering:
  • License, Co-develop, Outsource, Joint Venture, Sell

Funding organisation:
  • OTHER / NA

Infectious disease area:
  • GII
  • SSI

Geographic origin:
  • Eurasia


National territory and global licensing rights deals will be considered for phase 3 ready assets. Partner capable of supporting product development through phase 3 to approval and marketing within the relevant territory.

Clinical stage, UK based, biotechnology company focused on novel antimicrobials that prevent and treat infection

Preclinical: SPOR-COV immune boosting biotherapeutic for the prevention of viral respiratory infection, COVID-19. XF 73 dermal, treatment of bacterial skin infections. XF drug based bacterial biofilm active approaches.


What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!